翼状胬肉切除联合Ologen胶原基质植入与自体结膜瓣移植术的疗效及安全性

目的：分析翼状胬肉切除联合Ologen胶原基质植入与翼状胬肉切除联合自体结膜瓣移植术后的疗效及安全性。

方法：选取我院2017-01/2020-01收治的翼状胬肉患者80例87眼,随机分为观察组(40例44眼,接受翼状胬肉切除联合Ologen胶原基质植入术)与对照组(40例43眼,接受翼状胬肉切除联合自体结膜瓣移植术)。随访至术后12mo,比较两组患者最佳矫正视力、角膜散光度、表面不对称指数(SAI)、表面规则指数(SRI)、角膜上皮愈合、翼状胬肉复发及并发症发生情况。

结果：两组术后6、12mo时视力变化情况均无差异(P>0.05); 两组术后1、3mo时角膜散光度、SAI、SRI较术前均显著下降,观察组术后3mo时角膜散光度及术后1、3mo时SAI、SRI显著低于对照组(均P<0.05); 观察组术后1wk时角膜上皮愈合率显著高于对照组(73% vs 46%,P<0.05),至术后2wk两组角膜上皮均愈合; 两组术后12mo内未见翼状胬肉复发,术后6、12mo时翼状胬肉复发情况均无差异(P>0.05); 两组术后并发症发生率无差异(7% vs 14%,P>0.05)。

结论：翼状胬肉切除联合Ologen胶原基质植入与翼状胬肉切除联合自体结膜瓣移植术治疗翼状胬肉均可获得可靠的疗效,且安全性相当,但前者在改善角膜散光度、角膜创面规则形态上优势更显著,更利于角膜创面恢复规则形态。     

小梁切除术分别联合Ologen植入与丝裂霉素C治疗青光眼的有效性和安全性对比分析

目的　对比分析小梁切除术分别联合Ｏｌｏｇｅｎ植入与丝裂霉素Ｃ（ｍｉｔｏｍｙｃｉｎＣ,ＭＭＣ）治疗青光眼的有效性和安全性。方法　利用计算机检索Ｍｅｄｌｉｎｅ、ＥＭＢＡＳＥ、ＷｅｂｏｆＳｃｉｅｎｃｅ、ＣｏｃｈｒａｎｅＣｅｎｔｒａｌｏｆＣｏｎｔｒｏｌｌｅｄＴｒｉａｌｓ、ＧｏｏｇｌｅＳｃｈｏｌａｒ等数据库,检索时间均从建库至２０１４年１月,并追溯纳入文献的参考文献。将获得的临床对照研究,通过纳入和排除标准限定,经质量评价后,采用ＲｅｖＭａｎ５．０软件进行Ｍｅｔａ分析。结果　纳入６篇临床对照研究（小梁切除术联合Ｏｌｏｇｅｎ植入组１１４例,小梁切除术联合ＭＭＣ组１２３例）,质量评分均大于１６分,为高质量文献。Ｍｅｔａ分析结果显示,Ｏｌｏｇｅｎ植入组术后患者眼压减低,但眼压降低百分率与ＭＭＣ治疗组相比无明显差异。两组在青光眼药物种数治疗减少、手术成功率及术后并发症发生率等方面亦无明显差异。结论　小梁切除术联合Ｏｌｏｇｅｎ植入治疗青光眼在长期眼压控制成功率方面与小梁切除术联合ＭＭＣ治疗效果相当,在避免ＭＭＣ治疗引发的术后并发症方面无明显优势。     

Conjunctival Flap with Biodegradable Collagen Matrix Implantation for the Treatment of Scleromalacia after Periocular Surgery

Purpose: To report a new surgical procedure using biodegradable collagen matrix (Ologen) implantation with conjunctival flap for reconstruction of scleromalacia after periocular surgery.

Methods: A total of 26 areas of 25 eyes in 25 patients were included. We divided all eyes according to the preoperative extent of calcified plaque or scleral defect as follows: small, large, and large and severe. Morphologic outcomes were graded from 0 to 7, with higher scores indicating worse cosmetic outcomes.

Results: Mean follow-up period was 8.3 ± 5.6 months. No eyes showed recurrence or specific complications related to Ologen such as implant extrusion or allergic reaction. Minor complications such as flap vessel engorgement and flap hypertrophy were easily treated. Mean morphologic outcome scores were 1.8, 2.4, and 5.3 in groups 1, 2, and 3, respectively.

Discussion: The combined surgery may be an effective and safe procedure for the treatment of scleromalacia after periocular surgeries.     

Differential degeneration of rod/cone bipolar cells during retinal degeneration in Royal College of Surgeons rats

Dear Editor,Royal college of surgeons(RCS)rat is an inherited retinal degeneration rat caused by mutation of Mertk in the retinal pigment epithelial(RPE)cells^[1].In this dystrophic rat,the dysfunction of RPEs leads to the progressive death of photoreceptors,with rods initially affected.Many studies have attempt to transplant various stem cells.     

Comparison of bleb morphology by anterior segment optical coherence tomography and clinical outcome after phacotrabeculectomy with mitomycin C or Ologen implant

Purpose:To compare the bleb morphology by Anterior Segment Optical Coherence Tomography (ASOCT) and clinical outcome after Phacotrabeculectomy with either mitomycin C or Ologen implant.Methods:In a prospective interventional active controlled study, 93 patients aged 18 years and above underwent phacotrabeculectomy with either mitomycin C (53 eyes) or ologen implant (40 eyes), followed up for 12 months. The primary outcome measure was to note the evolution of bleb morphology by ASOCT in the two groups over 12 months. Secondary outcome measures were mean IOP, reduction in the need for anti-glaucoma medications, and complications seen in the two groups.Results:All parameters in the two groups were comparable preoperatively (P>0.05). Best corrected visual acuity at 12 months was 0.38±0.27 in mitomycin group and 0.31±0.23 in ologen group (P=0.151). Post-operative IOP at 12 months was 14.09±3.1mmHg (95%CI 13.22-14.97) in mitomycin group, and 13.25±2.5 mmHg (95%CI 12.40-14.30) in ologen group (P=0.254).The mean number of medications was 0.36±0.68 in mitomycin group and 0.38+/-0.70 in ologen group at 12 months (P=0.91). Overall success was achieved in 98.1 % of patients in mitomycin group and 90 % of patients in ologen group at 12 months. No major sight-threatening complications were noted in any group. AS-OCT imaging at 12 months showed multiform reflectivity with multiple large cystic spaces in both groups, with good IOP control.Conclusion:Phacotrabeculectomy using Mitomycin C and Ologen implant resulted in similar morphologic and functioning blebs at one year with comparable efficacy in controlling intraocular pressure.     

Efficacy and Safety of Sutureless Trabeculectomy with Using Porous Collagen (Ologen) in Management of Glaucoma Patients

PurposeThis study aims to investigate the safety, efficacy and feasibility of sutureless trabeculectomy using a porous collagen matrix that contains a connected porous structure (Ologen) in the control of intraocular pressure (IOP) in glaucoma patients.MethodsThe study includes 25 eyes from 24 patients that met the inclusion criteria. All eyes underwent trabeculectomy with the Ologen implant that provides a space with a dynamic and physiological aqueous reservoir system. The operation was considered successful if IOP is <15 mmHg without need of IOP-lowering drops at 18 months of follow-up.ResultsThe target IOP was achieved in 21 out of the 25 eyes (84%), the remaining four eyes all had an IOP of 16 mmHg at 18 months. Short-term complications consisted of seven cases of bleb leakage treated with bandage contact lens and one case of mild choroidal effusion which resolved after observation alone.ConclusionsWe can conclude that this technique can provide safety, effectiveness and short learning curve for ophthalmology trainees with lower incidence of perioperative and postoperative complications. Further studies may be required to prove stability and long-term efficacy in management of glaucoma patients.     

【In Press】 Trabeculectomy with collagen matrix implant versus mitomycin C in congenital glaucoma secondary

AIM: To compare the efficacy and safety of collagen matrix implant [Ologen (OLO) implant] versus mitomycin C (MMC) with subscleral trabeculectomy (SST) for the surgical treatment of congenital glaucoma (CG) in Surge Weber Syndrome (SWS). METHODS: A prospective comparative randomized study of 20 eyes of 16 patients with congenital glaucoma associated with SWS were divided into two groups. The first group (MMC group) included 10 eyes that were subjected to SST with MMC. The second group (OLO group) included 10 eyes that were subjected to trabeculectomy with a collagen matrix implant (OLO implant). Postoperative evaluation included intraocular pressure (IOP) level, bleb evaluation, complications, and the need for further medication or surgical intervention. RESULTS: The mean preoperative IOP was 29 (±3.1) in MMC and 29.8(±3.08) in OLO eyes. Mean 12-month percentage reduction in IOP was significant in both groups [57.9% and 56.3% with P?>?0.05]. At the end of the 12 postoperative follow-up month, in the MMC group, 80% of eyes achieved the complete success, 20% of eyes had qualified success with no failed surgery in comparison to (OLO group) which 70% of eyes achieved the complete success, 20% of eyes had qualified success with 10% failed surgery. In terms of complications, the MMC group had a higher rate of complications than the OLO group in the form of thin polycystic bleb in 6 eyes (60%), blebitis in only one eye (10%) treated with topical antibiotics, shallow AC in two eyes (20%). CONCLUSION: This study proves that the use of a collagen matrix implant yields equally effective results as MMC when combined with trabeculectomy for the treatment of congenital glaucoma in SWS. Furthermore, OLO implantation is safe and has low incidences of complications.     

Trabeculectomy with Ologen implant versus mitomycin C in congenital glaucoma secondary

AIM: To compare the efficacy and safety of collagen matrix implant [Ologen (OLO) implant] versus mitomycin C (MMC) with subscleral trabeculectomy (SST) for the surgical treatment of congenital glaucoma (CG) in Sturge- Weber Syndrome (SWS). METHODS: A prospective comparative randomized study of 20 eyes of 16 patients with CG associated with SWS was divided into two groups. The first group (MMC Group) included 10 eyes that were subjected to SST with MMC. The second group (OLO Group) included 10 eyes that were subjected to trabeculectomy with a collagen matrix implant (OLO implant). Postoperative evaluation included intraocular pressure (IOP) level, bleb evaluation, complications, and the need for further medication or surgical intervention. RESULTS: The mean preoperative IOP was 29±3.16 mm Hg in MMC and 29.8±3.08 mm Hg in OLO eyes. Mean 12-month percentage reduction in IOP was significant in both groups (57.9% and 56.3%). At the end of the 12 postoperative follow-up month, in the MMC Group, 80% of eyes achieved the complete success, 20% of eyes had qualified success with no failed surgery in comparison to OLO Group which 70% of eyes achieved the complete success, 20% of eyes had qualified success with 10% failed surgery. In terms of complications, the MMC Group had a higher rate of complications than the OLO Group in the form of thin polycystic bleb in 6 eyes (60%), blebitis in only one eye (10%) treated with topical antibiotics, shallow anterior chamber in two eyes (20%). CONCLUSION: This study proves that the use of a collagen matrix implant yields equally effective results as MMC when combined with trabeculectomy for the treatment of CG in SWS. Furthermore, OLO implantation is safe and has low incidences of complications.     

Ologen implant versus mitomycin C in combined trabeculectomy and phacoemulsification

Purpose:To comparatively evaluate in Indian eyes with coexisting cataract and primary open-angle glaucoma the outcome of mitomycin C (MMC) and Ologen implant as adjunctives in combined phacoemulsification with trabeculectomy.Methods:Eyes with primary open-angle glaucoma that underwent trabeculectomy and phacoemulsification with IOL implantation with either MMC application or Ologen implant between June 2019 and February 2020 were followed up for 12 months. Thirty-four eyes of 34 participants were studied. The primary outcome was intraocular pressure (IOP), and the secondary outcomes were the number of ocular hypotensives, best distance visual acuity (BDVA), and bleb morphology.Results:In 16 eyes treated with MMC and 18 eyes treated with Ologen implant, it was observed that the mean postoperative IOP (14.62 ± 2.89 mm Hg with MMC and 14.56 ± 4.14 mm Hg with Ologen implant) was not significantly different in both groups (P = 0.47). Number of ocular hypotensives and BDVA were also comparable between the two groups. However, bleb morphology was better with Ologen implantation. One eye in the MMC group developed hypotony which was conservatively managedConclusion:MMC and Ologen are both effective adjunctives in combined phaco-trabeculectomy. However, the Ologen implant provides better bleb health and safety.